Vol. 3 No. 7 (2023)
Reimbursement Reviews

Selumetinib (Koselugo)

Published July 20, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses selumetinib (Koselugo), 10 mg and 25 mg oral capsules.
  • Indication: For the treatment of pediatric patients aged 2 years and above, with neurofibromatosis type1 who have symptomatic, inoperable plexiform neurofibromas.